Publication Type:

Journal Article

Source:

Colloids and Surfaces B: Biointerfaces, Elsevier B.V., Volume 153, p.123-131 (2017)

URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013298094&doi=10.1016%2fj.colsurfb.2017.02.017&partnerID=40&md5=ca8e7616826f8314ad1a623691dfb4fd

Keywords:

analogs and derivatives, animal, Animals, antidiabetic agent, Biomaterials, Blood, chronic disease, closed loop systems, depot-, diabetes mellitus, Disease control, Drug delivery, drug delivery system, Drug Delivery Systems, Glucose, human, Humans, Hypoglycemic Agents, Injections, insulin, Insulin therapy, Medical problems, metabolism, Nanosystems, pancreas, physiology, PK/PD, Subcutaneous, subcutaneous drug administration, Type 1

Abstract:

<p>Diabetes mellitus (DM) is a metabolic disorder due to irregularities in glucose metabolism, as a result of insulin disregulation. Chronic DM (Type 1) is treated by daily insulin injections by subcutaneous route. Daily injections cause serious patient non-compliance and medication non-adherence. Insulin Depots (ID) are parenteral formulations designed to release the insulin over a specified period of time, to control the plasma blood glucose level for intended duration. Physiologically, pancreas produces and secretes insulin in basal and pulsatile mode into the blood. Delivery systems mimicking basal release profiles are known as open-loop systems and current marketed products are open-loop systems. Future trend in open-loop systems is to reduce the number of injections per week by enhancing duration of action, by modifying the depot properties. The next generation technologies are closed-loop systems that mimic the pulsatile mode of delivery by pancreas. In closed-loop systems insulin will be released in response to plasma glucose. This review focuses on future trend in open-loop systems; by understanding (a) the secretion of insulin from pancreas, (b) the insulin regulation normal and in DM, (c) insulin depots and (d) the recent progress in open-loop depot technology particularly with respect to nanosystems. © 2017 Elsevier B.V.</p>

Notes:

cited By 0

Cite this Research Publication

J. P.V, Shantikumar V Nair, and Dr. Kaladhar Kamalasanan, “Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes”, Colloids and Surfaces B: Biointerfaces, vol. 153, pp. 123-131, 2017.

207
PROGRAMS
OFFERED
6
AMRITA
CAMPUSES
15
CONSTITUENT
SCHOOLS
A
GRADE BY
NAAC, MHRD
8th
RANK(INDIA):
NIRF 2018
150+
INTERNATIONAL
PARTNERS